Trial Profile

Phase I Trial of PBF-1129 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PBF-1129 (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Palobiofarma

Most Recent Events

30 Apr 2025 Results assessing correlative analysis of immunophenotyping of peripheral blood changes during treatment, presented at the 116th Annual Meeting of the American Association for Cancer Research.
08 Feb 2024 Planned End Date changed from 31 Dec 2023 to 1 Aug 2024.
08 Feb 2024 Planned primary completion date changed from 31 Oct 2023 to 1 May 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com